Amphista Therapeutics appoints Dr Victoria Lovatt as Vice President of Intellectual Property

Cambridge, UK – January 30, 2023 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, has announced the appointment of Victoria Lovatt as Vice President of Intellectual Property.

Amphista’s CEO Nicola Thompson said, “I am delighted to welcome Victoria as our Vice President of Intellectual Property. Victoria is an IP strategist who brings a wealth of expertise from her experience working across the globe in the biotech and pharmaceuticals sectors. Victoria’s arrival further strengthens the Amphista team in Cambridge. Her specialist knowledge will support us as we continue our work to unlock the full potential of next generation TPD technology in order to bring transformative medicines to patients.”

Victoria commented on her appointment, “I am delighted to join Amphista’s world class team. Amphista is founded on transformational science and I’m looking forward to building on strong IP foundations to develop a broad strategic IP portfolio as we execute our mission of building the leading TPD company.”

Victoria joins Amphista from Mundipharma where she was Director of IP Strategy. Prior to that, she has held IP roles across the biotechnology and pharmaceuticals industries. Victoria is a Chartered UK Patent Attorney, a European patent attorney and a Singapore patent attorney. She holds a BSc (Hons) from Nottingham University in chemistry/biochemistry and a PhD in neuroimmunology from the University of Cambridge.

– Ends –

About Amphista Therapeutics
Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD) that address the challenges faced by earlier stage TPD research and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences and Eli Lilly & Company.

For more information, please visit:


Lynn Granito
Berry & Company Public Relations
212 253 8881